Last updated on December 2019

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers


Brief description of study

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Detailed Study Description

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, an intravenous PD-L1 inhibitor. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Clinical Study Identifier: NCT02655822

Find a site near you

Start Over

UCLA Medical Center

Los Angeles, CA United States
  Connect »

Stanford Cancer Institute

Stanford, CA United States
  Connect »

Yale University

New Haven, CT United States
  Connect »

Georgetown University

Washington, WA United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Carolina BioOncology Institute

Huntersville, NC United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

Monash Health

Clayton, Australia
  Connect »